12 July 2019 : Case report
Adding High-Dose Spironolactone to Tolvaptan Improves Acute Decompensated Heart Failure Due to Obstructive Hypertrophic Cardiomyopathy and Aortic Stenosis: A Case Report
Unusual setting of medical care
Katsuya Kajimoto1ABCDEFG*, Shigeru Otsubo2DFGDOI: 10.12659/AJCR.917060
Am J Case Rep 2019; 20:1006-1010
Abstract
BACKGROUND: In the setting of acute decompensated heart failure (ADHF), tolvaptan, a selective V₂ receptor antagonist, did not alter plasma renin activity or angiotensin II level, but significantly increased plasma aldosterone by the activation of V₁ₐ receptor, suggesting that a high-dose mineralocorticoid receptor antagonist (MRA) combined with a V₂ receptor antagonist might be of interest, especially in ADHF patients. However, in the setting of ADHF, the short-term and long-term efficacy of a high-dose MRA combined with tolvaptan remains unclear.
CASE REPORT: An 86-year-old woman with a history of chronic HF with a preserved ejection fraction due to obstructive hypertrophic cardiomyopathy and severe aortic stenosis was transferred to our hospital complaining of persistent dyspnea (New York Heart Association class IV). She did not respond to standard therapy with tolvaptan (15.0 mg/day). However, the present case demonstrated that adding high-dose spironolactone (100 mg/day) to low-dose tolvaptan (15.0 mg/day) is safe and well tolerated, resulting in an increase in urine output and improvement of the symptoms or signs of ADHF in a patient who was refractory to loop diuretics and tolvaptan.
CONCLUSIONS: The short- and long-term efficacy of high-dose spironolactone combined with low-dose tolvaptan may be associated with an attenuation of the aldosterone level, which is increased through V₁ₐ activation by vasopressin during tolvaptan administration.
Keywords: Aortic Stenosis, Subvalvular, Cardiomyopathy, Hypertrophic, Receptors, Vasopressin, spironolactone, Aged, 80 and over, Antidiuretic Hormone Receptor Antagonists, Aortic Valve Stenosis, Drug Therapy, Combination, Dyspnea, Mineralocorticoid Receptor Antagonists, Tolvaptan
In Press
02 Apr 2024 : Case report
Oculomotor Nerve Palsy Induced by a Cerebral Developmental Venous Anomaly: A Case Report and Comprehensive ...Am J Case Rep In Press; DOI: 10.12659/AJCR.943363
02 Apr 2024 : Case report
Langerhans Cell Histiocytosis in Sphenoid Sinus: Uncommon Bone InvolvementAm J Case Rep In Press; DOI: 10.12659/AJCR.942681
03 Apr 2024 : Case report
A Rare Case of Congenital Nephrogenic Diabetes Insipidus Associated with Aquaporin 2 Gene Mutation and Subs...Am J Case Rep In Press; DOI: 10.12659/AJCR.943597
03 Apr 2024 : Case report
Epigastric Pain and Dysphagia in a 36-Year-Old Man Due to Primary Esophageal Small Cell CarcinomaAm J Case Rep In Press; DOI: 10.12659/AJCR.943392
Most Viewed Current Articles
07 Mar 2024 : Case report
Neurocysticercosis Presenting as Migraine in the United StatesDOI :10.12659/AJCR.943133
Am J Case Rep 2024; 25:e943133
10 Jan 2022 : Case report
A Report on the First 7 Sequential Patients Treated Within the C-Reactive Protein Apheresis in COVID (CACOV...DOI :10.12659/AJCR.935263
Am J Case Rep 2022; 23:e935263
19 Jul 2022 : Case report
Atlantoaxial Subluxation Secondary to SARS-CoV-2 Infection: A Rare Orthopedic Complication from COVID-19DOI :10.12659/AJCR.936128
Am J Case Rep 2022; 23:e936128
23 Feb 2022 : Case report
Penile Necrosis Associated with Local Intravenous Injection of CocaineDOI :10.12659/AJCR.935250
Am J Case Rep 2022; 23:e935250